FDA Broadens Merck Pneumococcal Vaccine Label, Pressuring PFE Prevnar Franchise
What happened
The U.S. Food and Drug Administration approved an expanded indication for Merck's pneumococcal vaccine, extending its authorized use to at-risk pediatric and adolescent patients. The label expansion widens Merck's addressable market in a segment where Pfizer's Prevnar franchise has historically held dominant share. Pfizer has not issued a public statement in response to the regulatory action. The decision directly increases competitive pressure on one of Pfizer's core vaccine revenue lines.
The QL Read
PFE's composite signal sits at a neutral 47/100, and shares fell 2.76% on the day to $25.20 — this competitive label expansion from a rival arrives as the stock already shows no momentum support. With broad market breadth at 57.8% advancing, PFE's underperformance is stock-specific, not tape-driven.